174 related articles for article (PubMed ID: 21421726)
1. Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812.
Catafau AM; Bullich S; Nucci G; Burgess C; Gray F; Merlo-Pich E;
J Nucl Med; 2011 Apr; 52(4):526-34. PubMed ID: 21421726
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: part 2--ketanserin displacement.
Catafau AM; Danus M; Bullich S; Nucci G; Llop J; Abanades S; Cunningham VJ; Eersels JL; Pavia J; Farre M
J Nucl Med; 2006 Jun; 47(6):929-37. PubMed ID: 16741301
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 1--pseudoequilibrium interval and quantification methods.
Catafau AM; Danus M; Bullich S; Llop J; Perich J; Cunningham VJ; Plaza P; Penengo MM; Eersels JL; Squassante L; Ros D; Barbanoj M
J Nucl Med; 2006 Jun; 47(6):919-28. PubMed ID: 16741300
[TBL] [Abstract][Full Text] [Related]
4. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
5. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
6. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
[TBL] [Abstract][Full Text] [Related]
7. Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy.
Knauer CS; Campbell JE; Galvan B; Bowman C; Osgood S; Buist S; Buchholz L; Henry B; Wong EH; Shahid M; Grimwood S
Eur J Pharmacol; 2008 Sep; 591(1-3):136-41. PubMed ID: 18593577
[TBL] [Abstract][Full Text] [Related]
8. Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
Hodé Y; Benyamina A; Arbus C; Reimold M
Psychopharmacology (Berl); 2011 Oct; 217(3):315-21. PubMed ID: 21479533
[TBL] [Abstract][Full Text] [Related]
9. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
10. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof.
Suzuki H; Gen K; Inoue Y
J Psychopharmacol; 2013 Apr; 27(4):396-400. PubMed ID: 23427194
[TBL] [Abstract][Full Text] [Related]
13. Significant dissociation of brain and plasma kinetics with antipsychotics.
Tauscher J; Jones C; Remington G; Zipursky RB; Kapur S
Mol Psychiatry; 2002; 7(3):317-21. PubMed ID: 11920159
[TBL] [Abstract][Full Text] [Related]
14. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
Reimold M; Solbach C; Noda S; Schaefer JE; Bartels M; Beneke M; Machulla HJ; Bares R; Glaser T; Wormstall H
Psychopharmacology (Berl); 2007 Feb; 190(2):241-9. PubMed ID: 17111172
[TBL] [Abstract][Full Text] [Related]
15. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
[TBL] [Abstract][Full Text] [Related]
16. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature.
Stone JM; Davis JM; Leucht S; Pilowsky LS
Schizophr Bull; 2009 Jul; 35(4):789-97. PubMed ID: 18303092
[TBL] [Abstract][Full Text] [Related]
17. Dual-radiotracer translational SPECT neuroimaging. Comparison of three methods for the simultaneous brain imaging of D
Tsartsalis S; Tournier BB; Habiby S; Ben Hamadi M; Barca C; Ginovart N; Millet P
Neuroimage; 2018 Aug; 176():528-540. PubMed ID: 29723640
[TBL] [Abstract][Full Text] [Related]
18. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
[TBL] [Abstract][Full Text] [Related]
20. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
